CN116617191A - Application for resisting bacteria and inhibiting scar regeneration and preparation process thereof - Google Patents
Application for resisting bacteria and inhibiting scar regeneration and preparation process thereof Download PDFInfo
- Publication number
- CN116617191A CN116617191A CN202310619691.2A CN202310619691A CN116617191A CN 116617191 A CN116617191 A CN 116617191A CN 202310619691 A CN202310619691 A CN 202310619691A CN 116617191 A CN116617191 A CN 116617191A
- Authority
- CN
- China
- Prior art keywords
- antibacterial
- scar
- polyvinyl alcohol
- curcumin
- mesoporous silica
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 231100000241 scar Toxicity 0.000 title claims abstract description 128
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 108
- 238000011069 regeneration method Methods 0.000 title claims abstract description 105
- 230000008929 regeneration Effects 0.000 title claims abstract description 104
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 241000894006 Bacteria Species 0.000 title claims description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 140
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 140
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 88
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 73
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 73
- 229940109262 curcumin Drugs 0.000 claims abstract description 70
- 235000012754 curcumin Nutrition 0.000 claims abstract description 70
- 239000004148 curcumin Substances 0.000 claims abstract description 70
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 70
- 239000002105 nanoparticle Substances 0.000 claims abstract description 69
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 69
- 239000011159 matrix material Substances 0.000 claims abstract description 59
- 239000000084 colloidal system Substances 0.000 claims abstract description 48
- 229920001577 copolymer Polymers 0.000 claims abstract description 43
- 239000004005 microsphere Substances 0.000 claims abstract description 37
- 230000001681 protective effect Effects 0.000 claims abstract description 15
- 239000000758 substrate Substances 0.000 claims abstract description 14
- 239000000853 adhesive Substances 0.000 claims abstract description 13
- 230000001070 adhesive effect Effects 0.000 claims abstract description 13
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 115
- 229910052742 iron Inorganic materials 0.000 claims description 56
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 20
- VCCRNZQBSJXYJD-UHFFFAOYSA-N galangin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=CC=C1 VCCRNZQBSJXYJD-UHFFFAOYSA-N 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000004480 active ingredient Substances 0.000 claims description 16
- 239000000284 extract Substances 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 12
- 229920002635 polyurethane Polymers 0.000 claims description 12
- 239000004814 polyurethane Substances 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 12
- 241000972673 Phellodendron amurense Species 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 210000003056 antler Anatomy 0.000 claims description 10
- CIPSYTVGZURWPT-UHFFFAOYSA-N galangin Natural products OC1=C(Oc2cc(O)c(O)cc2C1=O)c3ccccc3 CIPSYTVGZURWPT-UHFFFAOYSA-N 0.000 claims description 10
- 239000003208 petroleum Substances 0.000 claims description 10
- SUYJZKRQHBQNCA-UHFFFAOYSA-N pinobanksin Natural products O1C2=CC(O)=CC(O)=C2C(=O)C(O)C1C1=CC=CC=C1 SUYJZKRQHBQNCA-UHFFFAOYSA-N 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 9
- 239000004745 nonwoven fabric Substances 0.000 claims description 9
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims description 9
- 238000001132 ultrasonic dispersion Methods 0.000 claims description 9
- 238000005303 weighing Methods 0.000 claims description 9
- 229920001651 Cyanoacrylate Polymers 0.000 claims description 8
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 8
- 239000008367 deionised water Substances 0.000 claims description 8
- 229910021641 deionized water Inorganic materials 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 241000282994 Cervidae Species 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 150000004676 glycans Chemical class 0.000 claims description 6
- 229920001282 polysaccharide Polymers 0.000 claims description 6
- 239000005017 polysaccharide Substances 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 244000241838 Lycium barbarum Species 0.000 claims description 4
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 4
- 241000972672 Phellodendron Species 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 4
- 239000007853 buffer solution Substances 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 238000007710 freezing Methods 0.000 claims description 4
- 230000008014 freezing Effects 0.000 claims description 4
- 239000008518 lycium barbarum polysaccharide Substances 0.000 claims description 4
- 238000002844 melting Methods 0.000 claims description 4
- 230000008018 melting Effects 0.000 claims description 4
- 238000013268 sustained release Methods 0.000 claims description 4
- 239000012730 sustained-release form Substances 0.000 claims description 4
- 238000010257 thawing Methods 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- 238000002604 ultrasonography Methods 0.000 claims description 3
- 230000007613 environmental effect Effects 0.000 claims description 2
- 230000000845 anti-microbial effect Effects 0.000 claims 4
- 239000004599 antimicrobial Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000035876 healing Effects 0.000 abstract description 14
- 230000035699 permeability Effects 0.000 abstract description 3
- 230000004060 metabolic process Effects 0.000 abstract description 2
- 208000027418 Wounds and injury Diseases 0.000 description 26
- 206010052428 Wound Diseases 0.000 description 25
- 210000003491 skin Anatomy 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 239000003814 drug Substances 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229920000915 polyvinyl chloride Polymers 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 6
- 208000032544 Cicatrix Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000017 hydrogel Substances 0.000 description 5
- 230000037387 scars Effects 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 4
- 206010053615 Thermal burn Diseases 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 235000017784 Mespilus germanica Nutrition 0.000 description 2
- 244000182216 Mimusops elengi Species 0.000 description 2
- 235000000560 Mimusops elengi Nutrition 0.000 description 2
- 235000007837 Vangueria infausta Nutrition 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000036573 scar formation Effects 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 150000002215 flavonoids Chemical group 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000003661 hair follicle regeneration Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002114 nanocomposite Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The utility model belongs to the technical field of medical application, and discloses an antibacterial and scar regeneration-inhibiting application and a preparation process thereof, wherein the antibacterial and scar regeneration-inhibiting application comprises a medical grade polyvinyl alcohol/iron-doped mesoporous silica nanoparticle/curcumin colloid matrix layer, a polylactic acid-glycolic acid copolymer/antibacterial and scar regeneration-inhibiting active ingredient-slow release microsphere, a substrate backing, an adhesive and a protective film; the application prepared by the preparation process has good air permeability, can ensure normal moisture metabolism of skin, ensures that the surface of a wound is healed in a moist environment, and has the advantages of high healing speed and short healing period.
Description
Technical Field
The utility model relates to the technical field of medical application, in particular to an antibacterial and scar regeneration inhibiting application and a preparation process thereof.
Background
The patch is usually made of non-woven fabric, and the paste medicine is smeared on the non-woven fabric and is stuck on the affected part of a patient, so that the medicine effect is exerted through the absorption of skin, and the pain of the patient is relieved. The patch has larger drug loading and good transdermal effect, but the commonly used patch is adhered to the skin by using rubber adhesives, which is easy to cause skin redness, allergy and the like and has poor comfort. The hydrogel is gel taking water as a dispersion medium, is a polymer network system, has large water absorption capacity, can provide good wet healing environment for wounds, has good air permeability, skin irritation and the like, and becomes an ideal application agent administration carrier.
In real life, burn, scald, traffic accident and mechanical injury occur, mild wounds can be healed by adopting medicines or other means, but in slightly serious cases, skin grafting operation can possibly be related to the damage to dermis, so that obvious scars can appear at skin grafting positions, skin taking positions and self-healing positions, and the illness state is controlled, but a large shadow is left for psychology.
From an aesthetic point of view, the scar color on the skin surface is often inconsistent with surrounding tissue, with some protrusions, some depressions, and stiffness, which is the most therapeutic cause of patients in clinical practice at present. Treatment of scars is very tricky and very satisfactory results are difficult to obtain. Theoretically, once formed, the scar, even though it is partially improved by the finest surgical procedure, cannot be completely eradicated. Therefore, various measures are taken to prevent scar formation to the maximum extent. The current market for preventing scarring from wounds, burns, scalds or post-operative wounds is a wide variety of drugs, and hormonal drugs such as corticosteroids are commonly used to help eliminate scarring, but must be considered for their side effects such as osteoporosis and pain.
Thus, more and more researchers have applied applications in the repair of skin surface lesions, such as: chinese patent No. cn20162039708. X discloses a scar patch for inhibiting scar hyperplasia; chinese patent No. CN201510883010.9 discloses a human-like collagen scar repairing silicone gel. Although the patents contain silica gel, the current silica gel scar paste products have poor scar repairing effect, and meanwhile, the patents are scar removing products after scar formation, and can not effectively inhibit the proliferation of the scar.
Disclosure of Invention
In view of the above, the present utility model provides an antibacterial and scar regeneration inhibiting application and a preparation process thereof. Aims at solving the technical problems that the prior scar applying scar has poor repairing effect, only can fade the scar and can not effectively inhibit the scar proliferation.
In order to achieve the above purpose, the utility model adopts the following technical scheme:
an antibacterial and scar regeneration inhibiting application comprises medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix layer, polylactic acid-glycolic acid copolymer/antibacterial, scar regeneration inhibiting active ingredient-slow release microsphere, substrate backing, adhesive and protective film; the antibacterial and scar regeneration inhibiting application is a square structure application, the medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix layer comprises polylactic acid-glycolic acid copolymer/antibacterial and scar regeneration inhibiting active ingredient-slow release microsphere, one side of the substrate backing is sequentially provided with the medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix layer and a protective film, and the substrate backing, the medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix layer and the protective film are connected through an adhesive; when in use, the protective film is uncovered, and the medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix layer is applied on the skin wound surface.
As a preferable technical scheme of the application for resisting bacteria and inhibiting scar regeneration, the substrate backing material is one of medical non-woven fabric, polyurethane and elastic non-woven fabric.
As a preferable technical scheme of the application for resisting bacteria and inhibiting scar regeneration, the protective film material is one of a pearlescent film, a PVC film or a PE film.
As a preferable technical scheme of the application for resisting bacteria and inhibiting scar regeneration, the adhesive material is cyanoacrylate.
As a preferred technical scheme of the application for resisting bacteria and inhibiting scar regeneration, the medical grade polyvinyl alcohol/iron doped mesoporous silica nano particles/curcumin colloidal matrix layer comprises 10-25% of medical grade polyvinyl alcohol, 3-5% of iron doped mesoporous silica nano particles and 4-7% of curcumin by mass fraction.
As a preferable technical scheme of the application for resisting bacteria and inhibiting scar regeneration, the polylactic acid-glycolic acid copolymer/the antibacterial and scar regeneration-inhibiting active ingredient-the antibacterial and scar regeneration-inhibiting active ingredient in the slow-release microsphere accounts for 2-8% in mass percent.
As a preferable technical scheme of the application for resisting bacteria and inhibiting scar regeneration, the active components for resisting bacteria and inhibiting scar regeneration comprise the following components in parts by weight: 0.1-3 parts of deer antler peptide, 0.1-5 parts of galangin, 0.1-5 parts of matrimony vine polysaccharide, 10-15 parts of phellodendron bark extract and 0.1-2 parts of antibacterial peptide.
As a preferable technical scheme of the preparation process of the application for resisting bacteria and inhibiting scar regeneration, the utility model specifically comprises the following steps:
step A: the medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix layer is prepared by mixing a certain amount of polyvinyl alcohol and deionized water, heating to 95-98 ℃ in a water bath, and preparing 40mg/mL polyvinyl alcohol solution; cooling to room temperature, adding iron-doped mesoporous silica nanoparticles and curcumin according to mass fraction, performing ultrasonic dispersion for 15-30min at 60-65 ℃ under the environmental condition, freezing for 60min at minus 20 ℃, rapidly heating, melting and standing for 30min, performing freeze thawing cycle operation for 4 times, and performing vacuum drying at 50 ℃ for 6h to obtain a medical grade polyvinyl alcohol/iron-doped mesoporous silica nanoparticle/curcumin colloidal matrix, namely a medical grade polyvinyl alcohol/iron-doped mesoporous silica nanoparticle/curcumin colloidal matrix layer;
and (B) step (B): the polylactic acid-glycolic acid copolymer/antibacterial and scar regeneration inhibiting active ingredient-slow release microsphere is prepared, and specifically comprises the following steps: weighing polylactic acid-glycolic acid copolymer which is 3-5 times of the total mass of the antibacterial and scar regeneration inhibiting active ingredients, fully dissolving the polylactic acid-glycolic acid copolymer in N, N-dimethylformamide solution, adding galangin, lycium barbarum polysaccharide and phellodendron bark extract according to mass fraction, stirring and reacting for 6 hours at 60 ℃, respectively adding 0.01mol/L phosphoric acid buffer solution containing antibacterial peptide and deer antler peptide, and stirring and reacting for 24 hours at 20 ℃ to obtain a product A; dialyzing the product A with deionized water for 24-48h, and drying to obtain polylactic acid-glycolic acid copolymer/antibacterial and scar regeneration inhibiting active ingredient-slow release microsphere;
step C: adding the prepared polylactic acid-glycolic acid copolymer/antibacterial scar regeneration inhibiting active ingredient-slow release microsphere into the prepared medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix, and performing ultrasonic dispersion for 10-15min to obtain an antibacterial scar regeneration inhibiting medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix layer;
step D: the medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix layer for inhibiting the regeneration of the antibacterial and scar is connected with a substrate backing and a protective film by using an adhesive, pressed into a film for forming, and die-cut and packaged, so that the antibacterial and scar regeneration inhibiting application with a square structure can be prepared.
As a preferable technical scheme of the preparation process of the application for resisting bacteria and inhibiting scar regeneration, the mass ratio of the polylactic acid-glycolic acid copolymer to the antibacterial and scar regeneration-inhibiting active ingredient-slow release microsphere to the medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle to the curcumin colloidal matrix is 2:7.
As a preferable technical scheme of the preparation process of the application for resisting bacteria and inhibiting scar regeneration, the drying method of the product A adopts reduced pressure drying for 8-12 hours.
As a preferred technical scheme of the preparation process of the application for resisting bacteria and inhibiting scar regeneration, the preparation method of the phellodendron extract specifically comprises the following steps: weighing cortex Phellodendri powder crushed to 60 meshes, adding 80% ethanol at a solid-to-liquid ratio of 1:205 (g/mL), heating in water bath at 80deg.C, extracting with 200W ultrasound for 20-30min, vacuum filtering, extracting with petroleum ether, discarding petroleum ether layer, repeatedly extracting for 2 times, and mixing the 2 filtrates to obtain cortex Phellodendri extractive solution.
According to the technical scheme, the utility model discloses an antibacterial and scar regeneration inhibiting application and a preparation process thereof, and the application prepared by the preparation process has good air permeability, can ensure normal moisture metabolism of skin, can provide local wet environment of scars, does not cause discomfort of the skin, and can be applied to scar parts for a long time; meanwhile, the prepared application enables the surface of the wound to heal in a moist environment, and has the advantages of high healing speed and short healing period; can be firmly attached to the surface of a body, can be fully attached to a wound surface, creates a moist microenvironment, inhibits the growth of microorganisms, effectively prevents the wound surface from being infected by bacteria, is easy to be completely torn off, effectively inhibits the formation of scars, and protects the wound surface to be complete.
Compared with the prior art, the utility model has the following technical effects:
1. compared with the traditional hydrogel application, the utility model adopts the nano composite material formed by the polyvinyl alcohol/iron doped mesoporous silica nano particles/curcumin as the carrier which is used as the effective component for resisting bacteria and inhibiting scar hyperplasia, not only shows colloid characteristics, provides necessary moist environment for the wound surface when being applied to the wound surface and quickens the healing speed of the wound surface, but also can release SiO in vivo 3 2- And Fe (Fe) 3+ ，SiO 3 2- Can stimulate proliferation and migration of endothelial cells and promote angiogenesis, thereby remarkably promoting wound healing; fe (Fe) 3+ Is the main component of human hemoglobin. It can transport oxygen and can be combined with SiO 3 2- And the curcumin has flavonoid structure to generate synergistic effect to stimulate endothelial cell proliferation, promote angiogenesis and hair follicle regeneration, and inhibit scar regeneration.
2. Compared with traditional loaded hormone medicines, the utility model has the advantages that the traditional Chinese medicine active ingredients and the biological active ingredients, such as galangin, medlar polysaccharide, phellodendron bark extract and deer antler peptide, are added, so that the effect of inhibiting scar regeneration is remarkably exerted, the effect of inhibiting microorganism growth is also remarkably exerted, a good healing environment can be provided for a wound surface, the healing speed is accelerated, and the medicine active ingredients and PLGA (polylactic acid-glycolic acid copolymer) are compounded to prepare the slow release microspheres, so that the sustained release microspheres can continuously and stably release medicines when the slow release microspheres are applied to the wound surface.
3. The antibacterial scar-inhibiting regeneration application prepared by the utility model is mainly applicable to wound surfaces such as abrasion, burns and scalds, and the like, can also be used for the later healing stages of wound surfaces such as postoperative wounds, ulcers, chronic bleeding wounds and the like, accelerates the repair of the wound surfaces, can diminish inflammation and sterilize, has no wound inflammatory reaction, and effectively promotes wound healing.
Detailed Description
The following description of the technical solutions in the embodiments of the present utility model will be clear and complete, and it is obvious that the described embodiments are only some embodiments of the present utility model, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the utility model without making any inventive effort, are intended to be within the scope of the utility model.
Example 1
An antibacterial and scar regeneration inhibiting application and its preparation method are provided, wherein the antibacterial and scar regeneration inhibiting application comprises medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix layer, polylactic acid-glycolic acid copolymer/antibacterial, scar regeneration inhibiting active ingredient-sustained release microsphere, medical non-woven fabrics, cyanoacrylate and pearlized film;
the medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix layer comprises polylactic acid-glycolic acid copolymer/antibacterial and scar regeneration inhibiting active ingredient-slow release microsphere, one side of the medical non-woven fabric is sequentially provided with the medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix layer and the pearlescent film, and the medical non-woven fabric, the medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix layer and the pearlescent film are connected through cyanoacrylate;
the antibacterial and scar regeneration inhibiting application is a square structure application;
the medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloidal matrix layer comprises 10%, 3% and 4% of medical grade polyvinyl alcohol, iron doped mesoporous silica nanoparticle and curcumin respectively by mass fraction.
The polylactic acid-glycolic acid copolymer/antibacterial, scar regeneration inhibiting active ingredient-slow release microsphere contains 2% of antibacterial, scar regeneration inhibiting active ingredient by mass fraction.
The antibacterial and scar regeneration inhibiting active ingredient comprises the following components in parts by weight: 1 part of antler peptide, 1 part of galangin, 1 part of matrimony vine polysaccharide, 10 parts of phellodendron extract and 0.1 part of antibacterial peptide; the preparation method of the phellodendron bark extract specifically comprises the following steps: weighing cortex Phellodendri powder crushed to 60 meshes, adding 80% ethanol at a solid-to-liquid ratio of 1:205 (g/mL), heating in water bath at 80deg.C, extracting with 200W ultrasonic for 20min, vacuum filtering, extracting with petroleum ether, discarding petroleum ether layer, repeatedly extracting for 2 times, and mixing the 2 filtrates to obtain cortex Phellodendri extractive solution.
The preparation process of the application for resisting bacteria and inhibiting scar regeneration specifically comprises the following steps: adding the prepared polylactic acid-glycolic acid copolymer/antibacterial scar regeneration inhibiting active ingredient-slow release microsphere into the prepared medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix, wherein the mass ratio of the polylactic acid-glycolic acid copolymer/antibacterial scar regeneration inhibiting active ingredient-slow release microsphere to the medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix is 2:7, and performing ultrasonic dispersion for 10min to obtain an antibacterial scar regeneration inhibiting medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix layer; the medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix layer for inhibiting the regeneration of the antibacterial and scar is connected with a substrate backing and a protective film by using an adhesive, pressed into a film for forming, and die-cut and packaged, so that the antibacterial and scar regeneration inhibiting application with a square structure can be prepared.
Example 2
An antibacterial and scar regeneration inhibiting application and a preparation process thereof are provided, wherein the antibacterial and scar regeneration inhibiting application comprises medical grade polyvinyl alcohol/iron doped mesoporous silica nano particles/curcumin colloid matrix layer, polylactic acid-glycolic acid copolymer/antibacterial and scar regeneration inhibiting active ingredient-slow release microspheres, medical polyurethane, cyanoacrylate and PVC film;
the medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix layer comprises polylactic acid-glycolic acid copolymer/antibacterial and scar regeneration inhibiting active ingredient-slow release microsphere, one side of polyurethane is sequentially provided with the medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix layer and a PVC film, and the polyurethane, the medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix layer and the PVC film are connected through cyanoacrylate;
the antibacterial and scar regeneration inhibiting application is a square structure application;
the medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloidal matrix layer comprises 25% of medical grade polyvinyl alcohol, 5% of iron doped mesoporous silica nanoparticle and 7% of curcumin by mass fraction.
The polylactic acid-glycolic acid copolymer/antibacterial, scar regeneration inhibiting active ingredient-the antibacterial and scar regeneration inhibiting active ingredient in the slow-release microspheres accounts for 8% by mass.
The antibacterial and scar regeneration inhibiting active ingredient comprises the following components in parts by weight: 3 parts of antler peptide, 5 parts of galangin, 5 parts of matrimony vine polysaccharide, 15 parts of phellodendron bark extract and 2 parts of antibacterial peptide; the preparation method of the phellodendron bark extract specifically comprises the following steps: weighing cortex Phellodendri powder crushed to 60 meshes, adding 80% ethanol at a solid-to-liquid ratio of 1:205 (g/mL), heating in water bath at 80deg.C, extracting with 200W ultrasound for 30min, vacuum filtering, extracting with petroleum ether, discarding petroleum ether layer, repeatedly extracting for 2 times, and mixing the 2 filtrates to obtain cortex Phellodendri extractive solution.
The preparation process of the application for resisting bacteria and inhibiting scar regeneration specifically comprises the following steps: adding the prepared polylactic acid-glycolic acid copolymer/antibacterial scar regeneration inhibiting active ingredient-slow release microsphere into the prepared medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix, wherein the mass ratio of the polylactic acid-glycolic acid copolymer/antibacterial scar regeneration inhibiting active ingredient-slow release microsphere to the medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix is 2:7, and performing ultrasonic dispersion for 15min to obtain an antibacterial scar regeneration inhibiting medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix layer; the medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix layer for inhibiting the regeneration of the antibacterial and scar is connected with a substrate backing and a protective film by using an adhesive, pressed into a film for forming, and die-cut and packaged, so that the antibacterial and scar regeneration inhibiting application with a square structure can be prepared.
Example 3
An antibacterial and scar regeneration inhibiting application and a preparation process thereof are provided, wherein the antibacterial and scar regeneration inhibiting application comprises medical grade polyvinyl alcohol/iron doped mesoporous silica nano particles/curcumin colloid matrix layer, polylactic acid-glycolic acid copolymer/antibacterial and scar regeneration inhibiting active ingredient-slow release microspheres, medical polyurethane, cyanoacrylate and PVC film;
the medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix layer comprises polylactic acid-glycolic acid copolymer/antibacterial and scar regeneration inhibiting active ingredient-slow release microsphere, one side of polyurethane is sequentially provided with the medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix layer and a PVC film, and the polyurethane, the medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix layer and the PVC film are connected through cyanoacrylate;
the antibacterial and scar regeneration inhibiting application is a square structure application;
the medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloidal matrix layer comprises 15% of medical grade polyvinyl alcohol, 4% of iron doped mesoporous silica nanoparticle and 5% of curcumin by mass fraction.
The polylactic acid-glycolic acid copolymer/antibacterial, scar regeneration inhibiting active ingredient-slow release microsphere contains 6% of antibacterial, scar regeneration inhibiting active ingredient by mass fraction.
The antibacterial and scar regeneration inhibiting active ingredient comprises the following components in parts by weight: 2.5 parts of antler peptide, 1.5 parts of galangin, 2 parts of medlar polysaccharide, 3.5 parts of phellodendron extract and 1.5 parts of antibacterial peptide; the preparation method of the phellodendron bark extract specifically comprises the following steps: weighing cortex Phellodendri powder crushed to 60 meshes, adding 80% ethanol at a solid-to-liquid ratio of 1:205 (g/mL), heating in water bath at 80deg.C, extracting with 200W ultrasonic for 25min, vacuum filtering, extracting with petroleum ether, discarding petroleum ether layer, repeatedly extracting for 2 times, and mixing the 2 filtrates to obtain cortex Phellodendri extractive solution.
The preparation process of the application for resisting bacteria and inhibiting scar regeneration specifically comprises the following steps: adding the prepared polylactic acid-glycolic acid copolymer/antibacterial scar regeneration inhibiting active ingredient-slow release microsphere into the prepared medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix, wherein the mass ratio of the polylactic acid-glycolic acid copolymer/antibacterial scar regeneration inhibiting active ingredient-slow release microsphere to the medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix is 2:7, and performing ultrasonic dispersion for 15min to obtain an antibacterial scar regeneration inhibiting medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix layer; the medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix layer for inhibiting the regeneration of the antibacterial and scar is connected with a substrate backing and a protective film by using an adhesive, pressed into a film for forming, and die-cut and packaged, so that the antibacterial and scar regeneration inhibiting application with a square structure can be prepared.
Example 4
The preparation method of the medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix layer comprises the steps of mixing a certain amount of polyvinyl alcohol and deionized water, and heating in a water bath to 95 ℃ to prepare a 40mg/mL polyvinyl alcohol solution; cooling to room temperature, adding iron-doped mesoporous silica nanoparticles and curcumin according to mass fraction, performing ultrasonic dispersion for 15min at 60 ℃, freezing for 60min at-20 ℃, rapidly heating, melting and standing for 30min, performing freeze thawing cycle operation for 4 times, and performing vacuum drying for 6h at 50 ℃ to obtain a medical grade polyvinyl alcohol/iron-doped mesoporous silica nanoparticle/curcumin colloid matrix, namely a medical grade polyvinyl alcohol/iron-doped mesoporous silica nanoparticle/curcumin colloid matrix layer; the remaining process parameters and procedures were exactly the same as in example 3.
Example 5
The preparation method of the medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloidal matrix layer comprises the steps of mixing a certain amount of polyvinyl alcohol and deionized water, and heating in a water bath to 98 ℃ to prepare a 40mg/mL polyvinyl alcohol solution; cooling to room temperature, adding iron-doped mesoporous silica nanoparticles and curcumin according to mass fraction, performing ultrasonic dispersion for 30min at 65 ℃ and freezing for 60min at-20 ℃, rapidly heating, melting and standing for 30min, performing freeze thawing cycle operation for 4 times, and performing vacuum drying at 50 ℃ for 6h to obtain a medical grade polyvinyl alcohol/iron-doped mesoporous silica nanoparticle/curcumin colloid matrix, namely a medical grade polyvinyl alcohol/iron-doped mesoporous silica nanoparticle/curcumin colloid matrix layer; the remaining process parameters and procedures were exactly the same as in example 3.
Example 6
The preparation method of the polylactic acid-glycolic acid copolymer/antibacterial scar regeneration inhibiting active ingredient-sustained release microsphere specifically comprises the following steps: weighing polylactic acid-glycolic acid copolymer which is 3 times of the total mass of the antibacterial and scar regeneration inhibiting active ingredients, fully dissolving the polylactic acid-glycolic acid copolymer in N, N-dimethylformamide solution, adding galangin, lycium barbarum polysaccharide and phellodendron amurense extract according to mass fraction, stirring and reacting for 6 hours at 60 ℃, respectively adding 0.01mol/L phosphoric acid buffer solution containing antibacterial peptide and deer antler peptide, and stirring and reacting for 12 hours at 20 ℃ to obtain a product A; dialyzing the product A with deionized water for 48h, and drying under reduced pressure for 10h to obtain polylactic acid-glycolic acid copolymer/antibacterial and scar regeneration inhibiting active ingredient-slow release microsphere; the remaining process parameters and procedure were exactly the same as in example 5.
Example 7
The polylactic acid-glycolic acid copolymer/antibacterial scar regeneration inhibiting active ingredient-slow release microsphere is prepared and specifically comprises the following steps of: weighing polylactic acid-glycolic acid copolymer which is 4 times of the total mass of the antibacterial and scar regeneration inhibiting active ingredients, fully dissolving the polylactic acid-glycolic acid copolymer in N, N-dimethylformamide solution, adding galangin, lycium barbarum polysaccharide and phellodendron amurense extract according to mass fraction, stirring and reacting for 6 hours at 60 ℃, respectively adding 0.01mol/L phosphoric acid buffer solution containing antibacterial peptide and deer antler peptide, and stirring and reacting for 18 hours at 20 ℃ to obtain a product A; dialyzing the product A with deionized water for 36h, and drying under reduced pressure for 10h to obtain polylactic acid-glycolic acid copolymer/antibacterial and scar regeneration inhibiting active ingredient-slow release microsphere; the remaining process parameters and procedure were exactly the same as in example 5.
Experiment
The antibacterial and scar regeneration-inhibiting application prepared in examples 1 to 7 of the present utility model was subjected to animal wound healing experiments separately from the existing commercially available polyurethane hydrogel application and sterile gauze.
9 male Sprague Dawley (SD) rats of 4 weeks of age (130 g.+ -.10 g) were purchased and after one week of adaptive feeding a skin defect model was established. Rats were randomly grasped and numbered and then weighed. Anesthetizing rats with 10% chloral hydrate (0.3 ml/kg), shaving the back hair of the rats with razor, sterilizing with iodophor, drawing a circle with diameter of 2cm with sterile dye (wound area is 3.14cm on average) 2 ) The full thickness skin in the circle was cut off with an ophthalmic scissors. Wounds are divided into the following groups: sterileGauze set, commercial polyurethane hydrogel application set, examples 1-7 set. The application is changed every three days. After the skin defect model was completed, the wound condition was recorded until the wound healed, and the experimental results are listed in table 1.
TABLE 1 statistical results of wound healing Condition in rats
As apparent from the data in Table 1, the experimental rats of the commercial polyurethane gel application group and the sterile gauze group have scars after healing, the healing period is 19 days and 22 days respectively, the healing period of the rats with the antibacterial and scar proliferation inhibition application prepared by the method is more than that of the rats with the antibacterial and scar proliferation inhibition application of the method, the healing period of the rats with the antibacterial and scar proliferation inhibition application of the method is 12 days on average, the healing period is shortened to 10 days to the shortest, and the wound surface area measured on the 3 rd day after the skin injury model is established is obvious.
In a comprehensive view, the antibacterial scar hyperplasia-inhibiting application prepared by the method can effectively promote wound healing, has the performance far superior to that of sterile gauze and polyurethane hydrogel application sold in the market, and is an ideal wound surface application.
In the present specification, each embodiment is described in a progressive manner, and each embodiment is mainly described in a different point from other embodiments, and identical and similar parts between the embodiments are all enough to refer to each other.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present utility model. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the utility model. Thus, the present utility model is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims (8)
1. An antibacterial scar regeneration inhibiting application, characterized in that: the application for resisting bacteria and inhibiting scar regeneration comprises medical grade polyvinyl alcohol/iron doped mesoporous silica nano particles/curcumin colloid matrix layer, polylactic acid-glycolic acid copolymer/antibacterial and scar regeneration inhibiting active ingredient-sustained release microsphere, substrate backing, adhesive and protective film;
the medical grade polyvinyl alcohol/iron doped mesoporous silica nano particles/curcumin colloid matrix layer comprises polylactic acid-glycolic acid copolymer/antibacterial and scar regeneration inhibiting active ingredient-slow release microspheres; the antibacterial and scar regeneration inhibiting active ingredient comprises the following components in parts by weight: 0.1-3 parts of deer antler peptide, 0.1-5 parts of galangin, 0.1-5 parts of matrimony vine polysaccharide, 10-15 parts of phellodendron bark extract and 0.1-2 parts of antibacterial peptide;
a medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix layer and a protective film are sequentially arranged on one side of the substrate back, and the substrate back, the medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix layer and the protective film are connected through an adhesive.
2. An antimicrobial scar regeneration inhibiting application as set forth in claim 1 wherein: the substrate backing material is one of medical non-woven fabric, polyurethane and elastic non-woven fabric; the protective film material is one of a pearlescent film, a PVC film or a PE film; the adhesive material is cyanoacrylate.
3. An antimicrobial scar regeneration inhibiting application as set forth in claim 1 wherein: the medical grade polyvinyl alcohol/iron doped mesoporous silica nano particles/curcumin colloidal matrix layer comprises 10% -25%, 3-5% and 4-7% of the components by mass fraction of the medical grade polyvinyl alcohol, the iron doped mesoporous silica nano particles and curcumin respectively.
4. An antimicrobial scar regeneration inhibiting application as set forth in claim 1 wherein: the polylactic acid-glycolic acid copolymer/antibacterial, scar regeneration inhibiting active ingredient-the antibacterial, scar regeneration inhibiting active ingredient in the slow release microsphere is 2-8% by mass fraction.
5. An antimicrobial scar regeneration inhibiting application as set forth in claim 1 wherein: the preparation method of the phellodendron extract specifically comprises the following steps: weighing cortex Phellodendri powder crushed to 60 meshes, adding 80% ethanol at a solid-to-liquid ratio of 1:205 (g/mL), heating in water bath at 80deg.C, extracting with 200W ultrasound for 20-30min, vacuum filtering, extracting with petroleum ether, discarding petroleum ether layer, repeatedly extracting for 2 times, and mixing the 2 filtrates to obtain cortex Phellodendri extractive solution.
6. A process for preparing an antibacterial scar-regeneration inhibiting dressing according to any one of claims 1 to 5, comprising the steps of:
step A: the medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix layer is prepared by mixing a certain amount of polyvinyl alcohol and deionized water, heating to 95-98 ℃ in a water bath, and preparing 40mg/mL polyvinyl alcohol solution; cooling to room temperature, adding iron-doped mesoporous silica nanoparticles and curcumin according to mass fraction, performing ultrasonic dispersion for 15-30min at 60-65 ℃ under the environmental condition, freezing for 60min at minus 20 ℃, rapidly heating, melting and standing for 30min, performing freeze thawing cycle operation for 4 times, and performing vacuum drying at 50 ℃ for 6h to obtain a medical grade polyvinyl alcohol/iron-doped mesoporous silica nanoparticle/curcumin colloidal matrix, namely a medical grade polyvinyl alcohol/iron-doped mesoporous silica nanoparticle/curcumin colloidal matrix layer;
and (B) step (B): the polylactic acid-glycolic acid copolymer/antibacterial and scar regeneration inhibiting active ingredient-slow release microsphere is prepared, and specifically comprises the following steps: weighing polylactic acid-glycolic acid copolymer which is 3-5 times of the total mass of the antibacterial and scar regeneration inhibiting active ingredients, fully dissolving the polylactic acid-glycolic acid copolymer in N, N-dimethylformamide solution, adding galangin, lycium barbarum polysaccharide and phellodendron bark extract according to mass fraction, stirring and reacting for 6 hours at 60 ℃, respectively adding 0.01mol/L phosphoric acid buffer solution containing antibacterial peptide and deer antler peptide, and stirring and reacting for 24 hours at 20 ℃ to obtain a product A; dialyzing the product A with deionized water for 24-48h, and drying to obtain polylactic acid-glycolic acid copolymer/antibacterial and scar regeneration inhibiting active ingredient-slow release microsphere;
step C: adding the prepared polylactic acid-glycolic acid copolymer/antibacterial scar regeneration inhibiting active ingredient-slow release microsphere into the prepared medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix, and performing ultrasonic dispersion for 10-15min to obtain an antibacterial scar regeneration inhibiting medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix layer;
step D: the medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloid matrix layer for inhibiting the regeneration of the antibacterial and scar is connected with a substrate backing and a protective film by using an adhesive, pressed into a film for forming, and die-cut and packaged, so that the antibacterial and scar regeneration inhibiting application with a square structure can be prepared.
7. The process for preparing an antibacterial and scar-suppressing patch according to claim 6, wherein: the mass ratio of polylactic acid-glycolic acid copolymer/antibacterial and scar regeneration inhibiting active ingredient-slow release microsphere to medical grade polyvinyl alcohol/iron doped mesoporous silica nanoparticle/curcumin colloidal matrix is 2:7.
8. The process for preparing an antibacterial and scar-suppressing patch according to claim 6, wherein: the product A is dried under reduced pressure for 8-12h.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310619691.2A CN116617191A (en) | 2023-05-30 | 2023-05-30 | Application for resisting bacteria and inhibiting scar regeneration and preparation process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310619691.2A CN116617191A (en) | 2023-05-30 | 2023-05-30 | Application for resisting bacteria and inhibiting scar regeneration and preparation process thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116617191A true CN116617191A (en) | 2023-08-22 |
Family
ID=87591665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310619691.2A Pending CN116617191A (en) | 2023-05-30 | 2023-05-30 | Application for resisting bacteria and inhibiting scar regeneration and preparation process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116617191A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105343926A (en) * | 2015-11-09 | 2016-02-24 | 广东泰宝医疗科技股份有限公司 | Scar patch containing nano silicon dioxide and preparation method of scar patch |
| US20160325010A1 (en) * | 2013-12-10 | 2016-11-10 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for adhering tissue surfaces and materials and biomedical uses thereof |
| CN113509317A (en) * | 2021-06-24 | 2021-10-19 | 王梦琪 | Antibacterial colloid patch for wound healing and preparation method thereof |
| CN114522200A (en) * | 2022-01-27 | 2022-05-24 | 华南理工大学 | Chinese wolfberry and almond pigment contained glycopeptide of Chinese wolfberry and almond for scald, and preparation method and application thereof |
-
2023
- 2023-05-30 CN CN202310619691.2A patent/CN116617191A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160325010A1 (en) * | 2013-12-10 | 2016-11-10 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for adhering tissue surfaces and materials and biomedical uses thereof |
| CN105343926A (en) * | 2015-11-09 | 2016-02-24 | 广东泰宝医疗科技股份有限公司 | Scar patch containing nano silicon dioxide and preparation method of scar patch |
| CN113509317A (en) * | 2021-06-24 | 2021-10-19 | 王梦琪 | Antibacterial colloid patch for wound healing and preparation method thereof |
| CN114522200A (en) * | 2022-01-27 | 2022-05-24 | 华南理工大学 | Chinese wolfberry and almond pigment contained glycopeptide of Chinese wolfberry and almond for scald, and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| IRAD.PAPEL 等: "《中药材规划化生产与管理（GAP）方法及技术》", 科学技术文献出版社, pages: 137 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Boateng et al. | Wound healing dressings and drug delivery systems: a review | |
| CN206214465U (en) | Skin or surface of a wound combine dressing and its external member | |
| KR100676937B1 (en) | Water soluble film for skin care and wound repair and method for their preparation | |
| CN105194719A (en) | Facial wound restoration dressing and plaster, and preparation methods thereof | |
| CN101537205A (en) | Degradable medical hemostatic non-viscous material and preparation method thereof | |
| CN107899003B (en) | Chitosan oligosaccharide medical wound care membrane and preparation method thereof | |
| CN110840827A (en) | Gynecological antibacterial repair gel and preparation method thereof | |
| Khorasani et al. | The effects of Aloe Vera cream on split-thickness skin graft donor site management: a randomized, blinded, placebo-controlled study | |
| CN104645320A (en) | Mussel mucoprotein gel for wound repair, and preparation method and application thereof | |
| WO2023198086A1 (en) | Antibacterial healing-promoting functionalized dressing and preparation method therefor | |
| RU2699362C2 (en) | Composition based on cerium dioxide nanoparticles and brown algae polysaccharides for treating wounds | |
| CN111317855B (en) | Three-dimensional composite spongy structure body for promoting diabetic ulcer wound healing and method | |
| CN104983722A (en) | Spraying film forming agent composition used for removing skin scars and preparation method of composition | |
| CN116617191A (en) | Application for resisting bacteria and inhibiting scar regeneration and preparation process thereof | |
| WO2000030578A1 (en) | Enzymatic treatment and prevention of hypertrophic skin | |
| KR101576244B1 (en) | aloin loaded wound dressing composition based on hydrogel and manufacturing method thereof | |
| CN102755414A (en) | Traditional Chinese medicine ointment for trauma wound and preparation method thereof | |
| CN113855849A (en) | Dressing composition and preparation method and application thereof | |
| CN112915100A (en) | A composition for preventing and treating scar | |
| WO2019080115A1 (en) | Long-acting sustained-release traditional chinese medicine cold compress for treating skin ulcer | |
| CN105233271A (en) | Anti-scaring andrias skin collagen burn cream and preparation method thereof | |
| CN113332042B (en) | Conductive network-silicone composite intelligent scar plaster and preparation method thereof | |
| CN111821504B (en) | Silver ion disinfection gel and preparation method thereof | |
| CN115554465B (en) | Freeze-dried absorbable collagen-based medical dressing and preparation method thereof | |
| EP4284339A1 (en) | Powdered collagen wound care compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |